Functioning and quality of life in patients with neuropathy associated with anti-MAG antibodies

YM Falzone, M Campagnolo, M Bianco, P Dacci, D Martinelli, M Ruiz, S Bocci, F Cerri, A Quattrini, G Comi, L Benedetti, F Giannini, G Lauria, E Nobile-Orazio, C Briani, R Fazio, N Riva

Research output: Contribution to journalArticle

Abstract

Although anti-myelin-associated glycoprotein (MAG) antibody neuropathy is reported as a slowly progressive disease, it can lead to significant disability and impairment of health-related quality of life (HR-QoL) and social participation. The aim of this cross-sectional study was to evaluate the functioning and HR-QoL determinants in 67 patients with anti-MAG neuropathy in terms of the International Classification of Functioning, Disability, and Health (ICF). Evaluations included: Medical Research Council (MRC) sum score, Sensory Modality Sum score (SMS), Berg balance scale (BBS), Fatigue Severity Scale (FSS), Visual Analogue Scale (VAS) for pain, 9-Hole Peg Test (9-HPT), 6-min Walk Distance (6MWD), Impact on Participation and Autonomy (IPA) and the physical component score (PCS) and mental component score (MCS) of the short-form-36 health status scale (SF-36) HR-QoL measure. In the regression models, 6MWD was the most reliable predictor of PCS, explaining the 52% of its variance, while the strongest determinants of 6MWD were BBS and FSS, explaining the 41% of its variance. Consistently, VAS and BBS were good predictor of PCS, explaining together 54% of its variance. FSS was the most reliable determinant of MCS, explaining 25% of its variance. SMS and MRC were not QoL determinants. The results of our study suggest that 6MWD and FSS might be considered as potential meaningful outcome measures in future clinical trials. Furthermore, neurorehabilitation interventions aimed at improving balance and walking performance, fatigue management, and specific pain relief therapy should be considered to ameliorate participation in social life and HR-QoL in anti-MAG neuropathy patients. © 2018, The Author(s).
Original languageEnglish
Pages (from-to)2927-2933
Number of pages7
JournalJournal of Neurology
Volume265
Issue number12
DOIs
Publication statusPublished - 2018

Fingerprint

Myelin-Associated Glycoprotein
Fatigue
Quality of Life
Antibodies
Biomedical Research
International Classification of Functioning, Disability and Health
Social Participation
Pain Measurement
Pain Management
Visual Analog Scale
Health Status
Walking
Cross-Sectional Studies
Outcome Assessment (Health Care)
Clinical Trials

Cite this

Functioning and quality of life in patients with neuropathy associated with anti-MAG antibodies. / Falzone, YM; Campagnolo, M; Bianco, M; Dacci, P; Martinelli, D; Ruiz, M; Bocci, S; Cerri, F; Quattrini, A; Comi, G; Benedetti, L; Giannini, F; Lauria, G; Nobile-Orazio, E; Briani, C; Fazio, R; Riva, N.

In: Journal of Neurology, Vol. 265, No. 12, 2018, p. 2927-2933.

Research output: Contribution to journalArticle

Falzone, YM, Campagnolo, M, Bianco, M, Dacci, P, Martinelli, D, Ruiz, M, Bocci, S, Cerri, F, Quattrini, A, Comi, G, Benedetti, L, Giannini, F, Lauria, G, Nobile-Orazio, E, Briani, C, Fazio, R & Riva, N 2018, 'Functioning and quality of life in patients with neuropathy associated with anti-MAG antibodies', Journal of Neurology, vol. 265, no. 12, pp. 2927-2933. https://doi.org/10.1007/s00415-018-9081-7
Falzone, YM ; Campagnolo, M ; Bianco, M ; Dacci, P ; Martinelli, D ; Ruiz, M ; Bocci, S ; Cerri, F ; Quattrini, A ; Comi, G ; Benedetti, L ; Giannini, F ; Lauria, G ; Nobile-Orazio, E ; Briani, C ; Fazio, R ; Riva, N. / Functioning and quality of life in patients with neuropathy associated with anti-MAG antibodies. In: Journal of Neurology. 2018 ; Vol. 265, No. 12. pp. 2927-2933.
@article{ea237899e76147cbb61bc3b69e598d51,
title = "Functioning and quality of life in patients with neuropathy associated with anti-MAG antibodies",
abstract = "Although anti-myelin-associated glycoprotein (MAG) antibody neuropathy is reported as a slowly progressive disease, it can lead to significant disability and impairment of health-related quality of life (HR-QoL) and social participation. The aim of this cross-sectional study was to evaluate the functioning and HR-QoL determinants in 67 patients with anti-MAG neuropathy in terms of the International Classification of Functioning, Disability, and Health (ICF). Evaluations included: Medical Research Council (MRC) sum score, Sensory Modality Sum score (SMS), Berg balance scale (BBS), Fatigue Severity Scale (FSS), Visual Analogue Scale (VAS) for pain, 9-Hole Peg Test (9-HPT), 6-min Walk Distance (6MWD), Impact on Participation and Autonomy (IPA) and the physical component score (PCS) and mental component score (MCS) of the short-form-36 health status scale (SF-36) HR-QoL measure. In the regression models, 6MWD was the most reliable predictor of PCS, explaining the 52{\%} of its variance, while the strongest determinants of 6MWD were BBS and FSS, explaining the 41{\%} of its variance. Consistently, VAS and BBS were good predictor of PCS, explaining together 54{\%} of its variance. FSS was the most reliable determinant of MCS, explaining 25{\%} of its variance. SMS and MRC were not QoL determinants. The results of our study suggest that 6MWD and FSS might be considered as potential meaningful outcome measures in future clinical trials. Furthermore, neurorehabilitation interventions aimed at improving balance and walking performance, fatigue management, and specific pain relief therapy should be considered to ameliorate participation in social life and HR-QoL in anti-MAG neuropathy patients. {\circledC} 2018, The Author(s).",
author = "YM Falzone and M Campagnolo and M Bianco and P Dacci and D Martinelli and M Ruiz and S Bocci and F Cerri and A Quattrini and G Comi and L Benedetti and F Giannini and G Lauria and E Nobile-Orazio and C Briani and R Fazio and N Riva",
year = "2018",
doi = "10.1007/s00415-018-9081-7",
language = "English",
volume = "265",
pages = "2927--2933",
journal = "Journal of Neurology",
issn = "0340-5354",
publisher = "Dr. Dietrich Steinkopff Verlag GmbH and Co. KG",
number = "12",

}

TY - JOUR

T1 - Functioning and quality of life in patients with neuropathy associated with anti-MAG antibodies

AU - Falzone, YM

AU - Campagnolo, M

AU - Bianco, M

AU - Dacci, P

AU - Martinelli, D

AU - Ruiz, M

AU - Bocci, S

AU - Cerri, F

AU - Quattrini, A

AU - Comi, G

AU - Benedetti, L

AU - Giannini, F

AU - Lauria, G

AU - Nobile-Orazio, E

AU - Briani, C

AU - Fazio, R

AU - Riva, N

PY - 2018

Y1 - 2018

N2 - Although anti-myelin-associated glycoprotein (MAG) antibody neuropathy is reported as a slowly progressive disease, it can lead to significant disability and impairment of health-related quality of life (HR-QoL) and social participation. The aim of this cross-sectional study was to evaluate the functioning and HR-QoL determinants in 67 patients with anti-MAG neuropathy in terms of the International Classification of Functioning, Disability, and Health (ICF). Evaluations included: Medical Research Council (MRC) sum score, Sensory Modality Sum score (SMS), Berg balance scale (BBS), Fatigue Severity Scale (FSS), Visual Analogue Scale (VAS) for pain, 9-Hole Peg Test (9-HPT), 6-min Walk Distance (6MWD), Impact on Participation and Autonomy (IPA) and the physical component score (PCS) and mental component score (MCS) of the short-form-36 health status scale (SF-36) HR-QoL measure. In the regression models, 6MWD was the most reliable predictor of PCS, explaining the 52% of its variance, while the strongest determinants of 6MWD were BBS and FSS, explaining the 41% of its variance. Consistently, VAS and BBS were good predictor of PCS, explaining together 54% of its variance. FSS was the most reliable determinant of MCS, explaining 25% of its variance. SMS and MRC were not QoL determinants. The results of our study suggest that 6MWD and FSS might be considered as potential meaningful outcome measures in future clinical trials. Furthermore, neurorehabilitation interventions aimed at improving balance and walking performance, fatigue management, and specific pain relief therapy should be considered to ameliorate participation in social life and HR-QoL in anti-MAG neuropathy patients. © 2018, The Author(s).

AB - Although anti-myelin-associated glycoprotein (MAG) antibody neuropathy is reported as a slowly progressive disease, it can lead to significant disability and impairment of health-related quality of life (HR-QoL) and social participation. The aim of this cross-sectional study was to evaluate the functioning and HR-QoL determinants in 67 patients with anti-MAG neuropathy in terms of the International Classification of Functioning, Disability, and Health (ICF). Evaluations included: Medical Research Council (MRC) sum score, Sensory Modality Sum score (SMS), Berg balance scale (BBS), Fatigue Severity Scale (FSS), Visual Analogue Scale (VAS) for pain, 9-Hole Peg Test (9-HPT), 6-min Walk Distance (6MWD), Impact on Participation and Autonomy (IPA) and the physical component score (PCS) and mental component score (MCS) of the short-form-36 health status scale (SF-36) HR-QoL measure. In the regression models, 6MWD was the most reliable predictor of PCS, explaining the 52% of its variance, while the strongest determinants of 6MWD were BBS and FSS, explaining the 41% of its variance. Consistently, VAS and BBS were good predictor of PCS, explaining together 54% of its variance. FSS was the most reliable determinant of MCS, explaining 25% of its variance. SMS and MRC were not QoL determinants. The results of our study suggest that 6MWD and FSS might be considered as potential meaningful outcome measures in future clinical trials. Furthermore, neurorehabilitation interventions aimed at improving balance and walking performance, fatigue management, and specific pain relief therapy should be considered to ameliorate participation in social life and HR-QoL in anti-MAG neuropathy patients. © 2018, The Author(s).

U2 - 10.1007/s00415-018-9081-7

DO - 10.1007/s00415-018-9081-7

M3 - Article

VL - 265

SP - 2927

EP - 2933

JO - Journal of Neurology

JF - Journal of Neurology

SN - 0340-5354

IS - 12

ER -